Patents by Inventor Sharon Ann TOWNSON

Sharon Ann TOWNSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220144849
    Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.
    Type: Application
    Filed: June 11, 2021
    Publication date: May 12, 2022
    Inventors: Gregory Lawrence VERDINE, Brian Roger BOWMAN, Mathew Edward SOWA, Joshua Alan Van Dyke BLODGETT, Keith Earl ROBISON, Dylan Talbot STILES, Jay Paul MORGENSTERN, Sharon Ann TOWNSON, Uddhav Kumar SHIGDEL
  • Publication number: 20220143202
    Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity.
    Type: Application
    Filed: June 10, 2021
    Publication date: May 12, 2022
    Inventors: Gregory Lawrence VERDINE, M. James NICHOLS, Dylan Talbot STILES, Neville John ANTHONY, Brian Roger BOWMAN, Mathew Edward SOWA, Sharon Ann TOWNSON
  • Patent number: 11059830
    Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for ex ample through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: July 13, 2021
    Assignee: Revolution Medicines, Inc.
    Inventors: Gregory Lawrence Verdine, Brian Roger Bowman, Mathew Edward Sowa, Joshua Alan Van Dyke Blodgett, Keith Earl Robison, Dylan Talbot Stiles, Jay Paul Morgenstern, Sharon Ann Townson, Uddhav Kumar Shigdel
  • Publication number: 20200347074
    Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for ex ample through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.
    Type: Application
    Filed: December 2, 2019
    Publication date: November 5, 2020
    Inventors: Gregory Lawrence VERDINE, Brian Roger BOWMAN, Mathew Edward SOWA, Joshua Alan Van Dyke BLODGETT, Keith Earl ROBISON, Dylan Talbot STILES, Jay Paul MORGENSTERN, Sharon Ann TOWNSON, Uddhav Kumar SHIGDEL
  • Patent number: 10533016
    Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 14, 2020
    Assignee: Revolution Medicines, Inc.
    Inventors: Gregory Lawrence Verdine, Brian Roger Bowman, Mathew Edward Sowa, Joshua Alan Van Dyke Blodgett, Keith Earl Robison, Dylan Talbot Stiles, Jay Paul Morgenstern, Sharon Ann Townson, Uddhav Kumar Shigdel
  • Publication number: 20180318434
    Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity.
    Type: Application
    Filed: July 16, 2018
    Publication date: November 8, 2018
    Inventors: Gregory Lawrence Verdine, M. James Nichols, Dylan Talbot Stiles, Neville John Anthony, Brian Roger Bowman, Mathew Edward Sowa, Sharon Ann Townson
  • Publication number: 20180273544
    Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.
    Type: Application
    Filed: January 8, 2016
    Publication date: September 27, 2018
    Inventors: Gregory Lawrence VERDINE, Brian Roger BOWMAN, Mathew Edward SOWA, Joshua Alan Van Dyke BLODGETT, Keith Earl ROBISON, Dylan Talbot STILES, Jay Paul MORGENSTERN, Sharon Ann TOWNSON, Uddhav Kumar SHIGDEL
  • Patent number: 10039839
    Abstract: The invention relates to macrocyclic compounds capable of modulating biological processes through binding to a presenter protein and a target protein. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiment, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: August 7, 2018
    Assignee: Warp Drive Bio, Inc.
    Inventors: Gregory Lawrence Verdine, Matthew James Nichols, Dylan Talbot Stiles, Neville John Anthony, Brian Roger Bowman, Mathew Edward Sowa, Sharon Ann Townson
  • Publication number: 20160199506
    Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 14, 2016
    Inventors: Gregory Lawrence VERDINE, Matthew James NICHOLS, Dylan Talbot STILES, Neville John ANTHONY, Brian Roger BOWMAN, Mathew Edward SOWA, Sharon Ann TOWNSON